These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 24666846)

  • 21. The psychometric properties of clinical rating scales used in multiple sclerosis.
    Sharrack B; Hughes RA; Soudain S; Dunn G
    Brain; 1999 Jan; 122 ( Pt 1)():141-59. PubMed ID: 10050902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study.
    Brochet B; Deloire MS; Bonnet M; Salort-Campana E; Ouallet JC; Petry KG; Dousset V
    Mult Scler; 2008 Nov; 14(9):1242-9. PubMed ID: 18653737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prospective assessment of the treatment of multiple sclerosis relapses with oral high-dose methylprednisolone: response and tolerability data].
    Pascual AM; Boscá I; Escutia M; Bernat A; Coret F; Casanova B
    Neurologia; 2008 Mar; 23(2):73-7. PubMed ID: 17641984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability.
    Hoogervorst EL; Zwemmer JN; Jelles B; Polman CH; Uitdehaag BM
    Mult Scler; 2004 Oct; 10(5):569-74. PubMed ID: 15471375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of patient-reported outcome measures in multiple sclerosis.
    Schäffler N; Schönberg P; Stephan J; Stellmann JP; Gold SM; Heesen C
    Acta Neurol Scand; 2013 Aug; 128(2):114-21. PubMed ID: 23398571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparisons of patient self-report, neurologic examination, and functional impairment in MS.
    Hoogervorst EL; van Winsen LM; Eikelenboom MJ; Kalkers NF; Uitdehaag BM; Polman CH
    Neurology; 2001 Apr; 56(7):934-7. PubMed ID: 11294932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a multiple sclerosis functional composite as a clinical trial outcome measure.
    Cutter GR; Baier ML; Rudick RA; Cookfair DL; Fischer JS; Petkau J; Syndulko K; Weinshenker BG; Antel JP; Confavreux C; Ellison GW; Lublin F; Miller AE; Rao SM; Reingold S; Thompson A; Willoughby E
    Brain; 1999 May; 122 ( Pt 5)():871-82. PubMed ID: 10355672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test.
    Drake AS; Weinstock-Guttman B; Morrow SA; Hojnacki D; Munschauer FE; Benedict RH
    Mult Scler; 2010 Feb; 16(2):228-37. PubMed ID: 20028710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Application of the Multiple Sclerosis Functional Composite in Debrecen].
    Mezei Z; Bereczki D; Csiba L; Csépány T
    Ideggyogy Sz; 2005 Mar; 58(3-4):113-8. PubMed ID: 15887414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of response of multiple sclerosis (MS) relapse to oral high-dose methylprednisolone: usefulness of MS functional composite and Expanded Disability Status Scale.
    Pascual AM; Boscá I; Coret F; Escutia M; Bernat A; Casanova B
    Eur J Neurol; 2008 Mar; 15(3):284-8. PubMed ID: 18290849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kurtzke scales revisited: the application of psychometric methods to clinical intuition.
    Hobart J; Freeman J; Thompson A
    Brain; 2000 May; 123 ( Pt 5)():1027-40. PubMed ID: 10775547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes of the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis.
    Patzold T; Schwengelbeck M; Ossege LM; Malin JP; Sindern E
    Acta Neurol Scand; 2002 Mar; 105(3):164-8. PubMed ID: 11886358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS.
    Rudick RA; Cutter G; Baier M; Fisher E; Dougherty D; Weinstock-Guttman B; Mass MK; Miller D; Simonian NA
    Neurology; 2001 May; 56(10):1324-30. PubMed ID: 11376182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The longitudinal relationship between the patient-reported Multiple Sclerosis Impact Scale and the clinician-assessed Multiple Sclerosis Functional Composite.
    Costelloe L; O'Rourke K; McGuigan C; Walsh C; Tubridy N; Hutchinson M
    Mult Scler; 2008 Mar; 14(2):255-8. PubMed ID: 17942522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical outcome measures for research in multiple sclerosis.
    Balcer LJ
    J Neuroophthalmol; 2001 Dec; 21(4):296-301. PubMed ID: 11756863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SaGAS, the Short and Graphic Ability Score: an alternative scoring method for the motor components of the Multiple Sclerosis Functional Composite.
    Vaney C; Vaney S; Wade DT
    Mult Scler; 2004 Apr; 10(2):231-42. PubMed ID: 15124771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value of gait analysis for measuring disease severity using inertial sensors in patients with multiple sclerosis: protocol for a systematic review and meta-analysis.
    Vienne-Jumeau A; Quijoux F; Vidal PP; Ricard D
    Syst Rev; 2019 Jan; 8(1):15. PubMed ID: 30621765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Evaluation of follow-up and evolution of multiple sclerosis].
    Couvreur G
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1143-51. PubMed ID: 11787348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tried and tested: the psychometric properties of the multiple sclerosis impact scale (MSIS-29) in a population-based study.
    Gray O; McDonnell G; Hawkins S
    Mult Scler; 2009 Jan; 15(1):75-80. PubMed ID: 18829636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical outcome measures in multiple sclerosis.
    Uitdehaag BM
    Handb Clin Neurol; 2014; 122():393-404. PubMed ID: 24507527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.